News

FDA Abbott Supera Self-Expanding Stent Peripheral Artery Disease

The U.S. Food and Drug Administration (FDA) approved Abbott’s Supera Peripheral Stent System to treat people with blocked blood vessels in the upper leg caused by peripheral artery disease (PAD...

Espirt Bioresorbable Vascular Scaffold BVS Peripheral Artery Disease PAD

Six-month results of the ESPRIT trial suggest a bioresorbable drug-eluting scaffold is effective in opening...

balloon catheters peripheral artery disease intact vascular tack-it

Intact Vascular Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, announced the start of enrollment in the Tack Optimized ...

stents peripheral clinical triady study S.M.A.R.T. nitinol stent cordis

Researchers at Saint Luke’s Mid America Heart Institute led a study that showed marked, long-term improvement...

October 23, 2013 — Vascular Interventional Advances (VIVA) Physicians, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and...

stents peripheral artery disease pad devices fda lifestent solo vascular bard

Bard Peripheral Vascular has sent an urgent Class I medical device recall notification letter informing customers of the problems of the LifeStent Solo ...

stents peripheral atherectomy devices artery disease PAD covidien everflex

Covidien released positive final results from its Durability II study and promising preliminary data from its Definitive AR trial at the Vascular Interventional Advances (VIVA) 2013 conference in...

boston scientific stents peripheral clinical trial study innova des drug-eluting

Launching a clinical trial expected to serve as the foundation for global regulatory approvals, a physician in...

stents peripheral peripheral artery disease pad clinical trial study bioflex

Biotronik announced it has completed patient enrollment in the iliac arm of its Bioflex-I trial. Under the supervision of Mark Burket, M.D. and chief, Cardiovascular Division at the University of...

stent peripheral artery disease treatment complete se medtronic

Expanding its role in the treatment of peripheral artery disease in the United States, Medtronic Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the Complete...

August 28, 2013 — Effective Oct. 1, Cook Medical’s Zilver PTX drug-eluting peripheral stent qualifies for new-technology add-on payments under Medicare’s hospital inpatient prospective...

Millenium Research Group, Stents (peripheral), Cath Lab,

According to Millennium Research Group (MRG), efforts to streamline the regulatory approval process in Japan have resulted in the recent entry of numerous devices in the Japanese...

Boston Scientific Corp. has completed enrollment in the SuperNOVA trial – a global, single arm, prospective, multicenter clinical trial evaluating the long-term (12-month) safety and...

Cook Medical is again shipping its Zilver PTX drug-eluting peripheral stent to medical centers in the United States, Japan, Europe and other major markets. The shipments follow a brief period...

Abbott Technologies Acquires IDEV Technologies

Abbott announced that it has entered into an agreement to purchase IDEV Technologies, a privately held company focused on developing next-generation medical devices for use by interventional...

Cordis Corp. announced it has completed the acquisition of Flexible Stenting Solutions Inc., whose technology provides Cordis with the opportunity to evolve the S.M.A.R.T. stent platform to...

Biotronik BIOFLEX-I IDE Clinical Trial Puslar-18 Peripheral Artery Disease

Biotronik announced the first U.S. implant of their Pulsar-18 self expanding stent in the BIOFLEX-I IDE clinical trial. Carlos Mena of Yale University Medical Center performed the procedure.

December 26, 2012 — Flexible Stenting Solutions Inc. (FSS) announced it gained CE mark in the European Union for its 6 French Reconstrainable FlexStent Femoropopliteal self-expanding...

More than half of patients treated for claudication or critical limb ischemia (CLI) with stenting of the superficial femoral artery (SFA) had primary patency at five years, says a recent study.

PAD Treatment Devices Stent Peripheral Cordis Corp. S.M.A.R.T., SMART, SFA stent

Cordis Corp. announced that the U.S. Food and Drug Administration (FDA) has approved the S.M.A.R.T. Control Vascular Stent Systems for use in the superficial femoral artery (SFA) and/or the...